US20170101660A1 - Enzyme-immobilized porous membrane and preparation method of antibiotics using the same - Google Patents
Enzyme-immobilized porous membrane and preparation method of antibiotics using the same Download PDFInfo
- Publication number
- US20170101660A1 US20170101660A1 US15/288,190 US201615288190A US2017101660A1 US 20170101660 A1 US20170101660 A1 US 20170101660A1 US 201615288190 A US201615288190 A US 201615288190A US 2017101660 A1 US2017101660 A1 US 2017101660A1
- Authority
- US
- United States
- Prior art keywords
- enzyme
- porous membrane
- derivative
- preparation
- immobilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 78
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 229940088710 antibiotic agent Drugs 0.000 title claims abstract description 25
- 102000004190 Enzymes Human genes 0.000 claims abstract description 54
- 108090000790 Enzymes Proteins 0.000 claims abstract description 54
- 239000000126 substance Substances 0.000 claims abstract description 47
- 230000003115 biocidal effect Effects 0.000 claims abstract description 41
- 238000001914 filtration Methods 0.000 claims abstract description 16
- 230000001737 promoting effect Effects 0.000 claims abstract description 13
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 9
- 239000000178 monomer Substances 0.000 claims description 41
- 239000011148 porous material Substances 0.000 claims description 19
- 125000000524 functional group Chemical group 0.000 claims description 16
- 125000003277 amino group Chemical group 0.000 claims description 15
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 claims description 13
- NGHVIOIJCVXTGV-ALEPSDHESA-N 6-aminopenicillanic acid Chemical compound [O-]C(=O)[C@H]1C(C)(C)S[C@@H]2[C@H]([NH3+])C(=O)N21 NGHVIOIJCVXTGV-ALEPSDHESA-N 0.000 claims description 12
- NGHVIOIJCVXTGV-UHFFFAOYSA-N 6beta-amino-penicillanic acid Natural products OC(=O)C1C(C)(C)SC2C(N)C(=O)N21 NGHVIOIJCVXTGV-UHFFFAOYSA-N 0.000 claims description 12
- 108010073038 Penicillin Amidase Proteins 0.000 claims description 12
- 125000004185 ester group Chemical group 0.000 claims description 12
- 125000000777 acyl halide group Chemical group 0.000 claims description 11
- DKLZRLRMFNWRFB-UHFFFAOYSA-N methyl 2-(4-hydroxyanilino)acetate Chemical compound COC(=O)CNC1=CC=C(O)C=C1 DKLZRLRMFNWRFB-UHFFFAOYSA-N 0.000 claims description 11
- 229930182555 Penicillin Natural products 0.000 claims description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 7
- 229940049954 penicillin Drugs 0.000 claims description 7
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N cephalosporin C Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 claims description 6
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 6
- 230000000379 polymerizing effect Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- NVIAYEIXYQCDAN-CLZZGJSISA-N 7beta-aminodeacetoxycephalosporanic acid Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](N)[C@@H]12 NVIAYEIXYQCDAN-CLZZGJSISA-N 0.000 claims description 2
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims 2
- 229940124587 cephalosporin Drugs 0.000 claims 2
- 150000001780 cephalosporins Chemical class 0.000 claims 2
- 230000003100 immobilizing effect Effects 0.000 abstract description 6
- 239000000376 reactant Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 21
- 238000000034 method Methods 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- LNHGLSRCOBIHNV-UHFFFAOYSA-N 4-[tris(4-aminophenyl)methyl]aniline Chemical compound C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 LNHGLSRCOBIHNV-UHFFFAOYSA-N 0.000 description 9
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920005597 polymer membrane Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000228150 Penicillium chrysogenum Species 0.000 description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
- 229960003022 amoxicillin Drugs 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 0 *C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C1=CC=C2C(=C1)C1(C3=C2C=CC(*)=C3)C2=C(C=CC(*)=C2)C2=C\C=C(*)/C=C\21.*CC*.C1=CC=C(C(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C1=CC=C(CC2=CC=CC=C2)C=C1.C1=CC=C(OC2=CC=CC=C2)C=C1.C1=CC=CC=C1.C1=CC=CC=C1.CC1=CC(CC2=CC=CC(C)=C2)=CC=C1.CC1=CC=CC=C1 Chemical compound *C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C.*C1=CC=C2C(=C1)C1(C3=C2C=CC(*)=C3)C2=C(C=CC(*)=C2)C2=C\C=C(*)/C=C\21.*CC*.C1=CC=C(C(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C1=CC=C(CC2=CC=CC=C2)C=C1.C1=CC=C(OC2=CC=CC=C2)C=C1.C1=CC=CC=C1.C1=CC=CC=C1.CC1=CC(CC2=CC=CC(C)=C2)=CC=C1.CC1=CC=CC=C1 0.000 description 2
- ALQLPWJFHRMHIU-UHFFFAOYSA-N 1,4-diisocyanatobenzene Chemical compound O=C=NC1=CC=C(N=C=O)C=C1 ALQLPWJFHRMHIU-UHFFFAOYSA-N 0.000 description 2
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 2
- SBPHDJANZYGCGZ-UHFFFAOYSA-N 1-isocyanato-4-[tris(4-isocyanatophenyl)methyl]benzene Chemical compound C1=CC(N=C=O)=CC=C1C(C=1C=CC(=CC=1)N=C=O)(C=1C=CC(=CC=1)N=C=O)C1=CC=C(N=C=O)C=C1 SBPHDJANZYGCGZ-UHFFFAOYSA-N 0.000 description 2
- 108700023418 Amidases Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 235000002233 Penicillium roqueforti Nutrition 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 150000007824 aliphatic compounds Chemical group 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001491 aromatic compounds Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002114 nanocomposite Substances 0.000 description 2
- 238000005935 nucleophilic addition reaction Methods 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052710 silicon Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- HLBLWEWZXPIGSM-UHFFFAOYSA-N 4-Aminophenyl ether Chemical compound C1=CC(N)=CC=C1OC1=CC=C(N)C=C1 HLBLWEWZXPIGSM-UHFFFAOYSA-N 0.000 description 1
- PJLYVFDXWMHBBI-UHFFFAOYSA-O CC1(C)SC2C(CC(=O)C(N)C3=CC=C(O)C=C3)CN2C1C(=O)O.CC1(C)SC2C(N)C(=O)N2C1C(=O)O.[CH2+]OC(=O)C(N)C1=CC=C(O)C=C1 Chemical compound CC1(C)SC2C(CC(=O)C(N)C3=CC=C(O)C=C3)CN2C1C(=O)O.CC1(C)SC2C(N)C(=O)N2C1C(=O)O.[CH2+]OC(=O)C(N)C1=CC=C(O)C=C1 PJLYVFDXWMHBBI-UHFFFAOYSA-O 0.000 description 1
- NHPNNXJKMFPCQW-KGVCMTNLSA-L CC1(C)SC2[C@H](CC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(=O)[O-].CC1(C)SC2[C@H]([NH3+])C(=O)N2[C@H]1C(=O)[O-].O.O=C([O-])CC1=CC=CC=C1.[K+].[K+] Chemical compound CC1(C)SC2[C@H](CC(=O)CC3=CC=CC=C3)C(=O)N2[C@H]1C(=O)[O-].CC1(C)SC2[C@H]([NH3+])C(=O)N2[C@H]1C(=O)[O-].O.O=C([O-])CC1=CC=CC=C1.[K+].[K+] NHPNNXJKMFPCQW-KGVCMTNLSA-L 0.000 description 1
- IXLDASZIFPDBEH-UHFFFAOYSA-N N#COC1=CC=C(C(C2=CC=C(N=C=O)C=C2)(C2=CC=C(N=C=O)C=C2)C2=CC=C(N=C=O)C=C2)C=C1 Chemical compound N#COC1=CC=C(C(C2=CC=C(N=C=O)C=C2)(C2=CC=C(N=C=O)C=C2)C2=CC=C(N=C=O)C=C2)C=C1 IXLDASZIFPDBEH-UHFFFAOYSA-N 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P37/00—Preparation of compounds having a 4-thia-1-azabicyclo [3.2.0] heptane ring system, e.g. penicillin
- C12P37/04—Preparation of compounds having a 4-thia-1-azabicyclo [3.2.0] heptane ring system, e.g. penicillin by acylation of the substituent in the 6 position
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- C12N11/093—Polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/84—Penicillin amidase (3.5.1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01011—Penicillin amidase (3.5.1.11), i.e. penicillin-amidohydrolase
Definitions
- the present disclosure relates to an enzyme-immobilized porous membrane and a preparation method of antibiotics using the same, and more specifically, to an enzyme-immobilized porous membrane prepared by immobilizing a specific enzyme through filtration, and a preparation method of antibiotics with a high yield using the enzyme-immobilized porous membrane.
- Enzymes are generally useful for various reactions due to high steric and chemical selectivity, and have been used as a catalyst to promote a reaction rate under a mild reaction condition.
- the enzymes have a high cost, it is economically difficult to be used in an industrially large amount.
- most of the enzymes have a limitation in being used for an organic chemical reaction since they are not dissolved in organic solvents. Accordingly, a number of researches to immobilize the enzymes have been conducted to enhance activity and stability of the enzymes and reuse the enzymes.
- the first method is to adsorb the enzyme on a surface of the polymer membrane
- the second method is to attach the enzyme to the polymer membrane via a covalent bond by modifying the enzyme
- the third method is an entrapping method in which the enzyme is physically entrapped in pores of the polymer membrane.
- the adsorption method Since the method of adsorbing the enzyme on the surface of the membrane via a non-covalent bond is the easiest and simplest, a number of researches into the adsorption method have been conducted, but the adsorption method is disadvantageous in that the enzyme may be easily leached away, and has relatively low stability.
- the immobilization method is effective to improve an immobilization rate and an immobilization maintenance rate of the enzyme and is effective in view of economical aspect since the immobilization process is relatively simple.
- Penicillin-based antibiotics are ⁇ -lactam-based antibiotics produced by blue mold (Penicillium notatum), etc., and may be synthesized from Penicillium notatum and Penicillium chrysogenum that are called the blue mold.
- the antibiotics are synthesized by treating a derivative in a solution state through step-by-step reactions.
- this preparation method causes side reactions such as hydrolysis reaction and thus the final antibiotic substance is produced in a remarkably low yield.
- the enzyme-immobilized porous membrane is used to stably immobilize the enzyme capable of promoting reactivity of the antibiotic substance in the porous membrane, thereby improving the reactivity, such that the antibiotic that is a final substance may have an improved yield.
- an enzyme-immobilized porous membrane in which an enzyme promoting a synthesis reaction of an antibiotic substance is immobilized, wherein the porous membrane is three-dimensionally interconnected by pores, the porous membrane forms a three dimensional network by polymerizing a first monomer and a second monomer each having two to four functional groups, the functional group of the first monomer is an amino group, the functional group of the second monomer is an isocyanate group, an acyl halide group or an ester group, the first monomer and/or the second monomer has four functional groups, and the enzyme is at least one selected from the group consisting of penicillin G acylase, penicillin V acylase, and cephalosporin C acylase.
- a preparation method of antibiotics includes: (B) permeating a derivative solution of an antibiotic substance through the enzyme-immobilized porous membrane as described above.
- the enzyme capable of promoting the synthesis reaction of the antibiotic substance is able to be stably immobilized in the porous membrane by using the dead-end filtration.
- the antibiotics with a high yield by preparing the antibiotics through the dead-end filtration using the enzyme-immobilized porous membrane.
- FIG. 1 illustrates a dead-end cell filtration system for immobilizing an enzyme according to an exemplary embodiment of the present disclosure.
- FIG. 2 is a diagram illustrating a preparation method in which the enzyme is immobilized in the porous membrane according to the exemplary embodiment of the present disclosure.
- FIG. 3 is a graph illustrating results obtained by adsorbing nitrogen onto or desorbing nitrogen from a PGA-immobilized porous membrane according to Example 1 to measure an adsorption degree or a desorption degree.
- FIG. 4 is a graph illustrating results obtained by measuring a size of pores formed on the PGA-immobilized porous membrane according to Example 1.
- FIG. 5A is an image illustrating a cross section of the PGA-immobilized porous membrane according to Example 1
- FIG. 5B is an image illustrating results obtained by elemental mapping on the PGA-immobilized porous membrane according to Example 1 using an energy-dispersive X-ray spectrometer.
- FIG. 6 is a graph illustrating results obtained by measuring a yield of the antibiotic prepared by Example 2.
- an enzyme-immobilized porous membrane in which an enzyme promoting a synthesis reaction of an antibiotic substance is immobilized, wherein the porous membrane is three-dimensionally interconnected by pores, the porous membrane forms a three-dimensional network by polymerizing a first monomer and a second monomer each having two to four functional groups, the functional group of the first monomer is an amino group, the functional group of the second monomer is an isocyanate group, an acyl halide group or an ester group, at least one of the first monomer or the second monomer has four functional groups, and the enzyme is at least one selected from the group consisting of penicillin G acylase, penicillin V acylase, and cephalosporin C acylase.
- the enzymes are characterized by promoting a synthesis reaction of an antibiotic substance, and among them, the penicillin G acylase is an enzyme capable of promoting reactions of Reaction Schemes 1 and 2 below:
- carboxylic acid and 6-aminopenicillanic acid may be produced by promoting a hydrolysis reaction of an amide group.
- a reaction of synthesizing penicillin-based amoxicillin which is a beta-lactam-based antibiotic may be promoted, and specifically, the penicillin may be synthesized by promoting a reaction of an ester group of p-hydroxyphenylglycine methyl ester (PHPGME) and an amine group of 6-APA to form an amide group:
- PHPGME p-hydroxyphenylglycine methyl ester
- the penicillin G acylase enzyme may act as a catalyst effective for promoting reactivity in synthesizing the penicillin-based antibiotic, but has a problem in that stability thereof is degraded due to the hydrolysis as shown in Reaction Scheme 1 above.
- the enzyme is immobilized in the porous membrane to prevent decomposition or leaching of the enzyme, such that stability of the enzyme may be secured.
- antibiotics with a high yield may be prepared only by a relatively simple process in which a derivative of the antibiotic substance is permeated through the porous membrane in which the enzyme having secured stability is immobilized.
- the enzyme-immobilized porous membrane described above in the present disclosure includes the porous membrane forming a three-dimensional network and an enzyme that is trapped in the pores of the porous membrane.
- the porous membrane may include the pores having a size of 5 to 100 nm while forming a three-dimensionally cross-linked monolith, and the pores may be connected to each other, such that the enzyme immobilized in the porous membrane is able to be in contact with reaction substrates in all directions, and a solution may be easily spread, which prevent a problem that substance transport is degraded due to the enzyme blocking the pores.
- the size of the pore is 20 to 50 nm (Membrane-Based Synthesis of Nanomaterials, Charles R. Martin), and the porous membrane of the present disclosure is characterized by immobilizing various sizes of enzymes since it has various ranges of nano pores having a size of 5 to 100 nm as well as pores having a size in micro range.
- the porous membrane of the present disclosure may be obtained by mixing an organic sol with a polymer solution to obtain a micro porous membrane, the organic sol consisting of an organic network structure in which the first monomer having an amino group is polymerized with the second monomer having an isocyanate group, an acyl halide group or an ester group that is the functional group polymerizable with the amino group, and removing the polymer from the micro porous membrane by using water.
- the first monomer may have two to four amino groups
- the second monomer may have two to four functional groups selected from the group consisting of the isocyanate group, the acyl halide group, and the ester group.
- the first monomer having two to four amino groups may be C 1 -C 100 aliphatic compound substituted with two to four amino groups or C6-C 100 aromatic compound substituted with two to four amino groups.
- the second monomer having two to four isocyanate groups, the two to four acyl halide groups, or the two to four ester groups may be C 1 -C 100 aliphatic compound substituted with two to four isocyanate groups, the two to four acyl halide groups, or the two to four ester groups or C6-C 100 aromatic compound substituted with two to four isocyanate groups, the two to four acyl halide groups, or the two to four ester groups.
- the first monomer and the second monomer may be compounds represented by Chemical Formulas 1 to 9 below:
- R is an amino group, an isocyanate group, an acyl halide group or an ester group.
- the first monomer and the second monomer may be a compound represented by Chemical
- R is an amino group, an isocyanate group, an acyl halide group or an ester group, and n is 0 or 1.
- the first monomer and the second monomer may be polymerized by a nucleophilic addition or substitution reaction between the amino group of the first monomer and the isocyanate group, the acyl halide group or the ester group of the second monomer, and polymers to be produced may cause additional nucleophilic addition or substitution reaction by non reacted negative ( ⁇ ), positive (+) functional groups to generate a crosslinking reaction between the polymers.
- the monomer having the four functional groups may form a kind of crosslinking point as a tetrahedral structure, and may form the three-dimensional organic network structure linked by a strong covalent bond on the basis of the crosslinking point.
- the organic network structure formed by the polymerization reaction between the first monomer and the second monomer may be three-dimensionally polymerized and cross-linked to have a number of fine pores and a large specific surface area, and to have excellent chemical resistance, heat resistance, and durability by a high crosslinking rate and the strong covalent bond.
- the monomer having two to four amino groups may be, for example, tetrakis(4-aminophenyl)methane (TAPM), p-phenylene diamine (PDA), or 4,4′-oxydianiline (ODA), but these examples thereof are not limited thereto.
- TAPM tetrakis(4-aminophenyl)methane
- PDA p-phenylene diamine
- ODA 4,4′-oxydianiline
- the monomer having two to four isocyanate groups may be, for example, p-phenylene diisocyanate (PDI), hexamethylene diisocyanate (HDI), or tetrakis(4-isocyanatophenyl) methane (TIPM), but these examples thereof are not limited thereto.
- PDI p-phenylene diisocyanate
- HDI hexamethylene diisocyanate
- TIPM tetrakis(4-isocyanatophenyl) methane
- the porous membrane may be formed by polymerizing a monomer represented by Chemical Formula 11 below and the monomer having two isocyanate groups:
- X is a carbon atom or a silicon atom.
- the porous membrane may be formed by polymerizing the monomer having two amino groups and a monomer represented by Chemical Formula 12 below:
- X is a carbon atom or a silicon atom.
- the porous membrane may have a flat sheet structure or a hollow fiber membrane structure.
- the porous membrane may have a single layered structure or a plurality of layered structure.
- a preparation method of antibiotics including: (B) permeating a derivative solution of an antibiotic substance through the enzyme-immobilized porous membrane.
- the preparation method preferably further includes step (A) of preparing the derivative solution of the antibiotic substance.
- the derivative of the antibiotic substance is prepared in a solution state, and is treated with step-by-step reactions, thereby preparing the antibiotics.
- the preparation method of the antibiotics through the step-by-step reactions has problems in that the finally produced antibiotic substance has a remarkably low yield, and a large amount of impurities are caused due to the hydrolysis reaction or the addition reaction of the enzyme.
- stability of the enzyme is firstly secured by immobilizing the enzyme in the porous membrane, and then, the antibiotics with a high yield are prepared only by a simple process of permeating the derivative of the antibiotic substance through the enzyme-immobilized porous membrane.
- step (A) is a step of preparing the derivative solution of the antibiotic substance capable of preparing the antibiotic substance.
- the derivative of the antibiotic substance preferably includes the first derivative and the second derivative, and the first derivative and the second derivative may be different from each other, and the first derivative or the second derivative may be at least one selected from the group consisting of 6-aminopenicillanic acid (6-APA), p-hydroxyphenylglycine methyl ester (PHPGME), 7-aminodesacetoxycephalosporanic acid, and phenylglycine.
- 6-APA 6-aminopenicillanic acid
- PHPGME p-hydroxyphenylglycine methyl ester
- 7-aminodesacetoxycephalosporanic acid phenylglycine
- the step (A) may include (a-1) preparing a first derivative solution; (a-2) preparing a second derivative solution; and (a-3) mixing the first derivative solution with the second derivative solution.
- the step (a-1) is a step of preparing the first derivative solution, wherein the first derivative solution preferably has a concentration of 1 to 20 mM by adding a solvent to the first derivative.
- concentration of the first derivative solution is less than 1 mM, it is not preferred since the concentration is too thin, reactivity with the enzyme may be degraded, and when the concentration thereof is more than 20 mM, an amount of the reaction substance is increased as compared to an amount of the enzyme.
- the step (a-2) is a step of preparing the second derivative solution, wherein the second derivative solution preferably has a concentration of 1 to 20 mM by adding a solvent to the second derivative, which is similar to the step (a-1).
- the solvent is preferably distilled water, but the present disclosure is not limited thereto.
- the step (a-3) is a step of mixing the first derivative solution with the second derivative solution, wherein the first derivative and the second derivative are preferably mixed at a molar (M) ratio of 1:1 to 3.
- M molar ratio
- the first derivative is 6-aminopenicillanic acid
- the second derivative is p-hydroxyphenylglycine methyl ester
- the 6-amino-penicillanic acid is mixed with the p-hydroxyphenylglycine methyl ester at a molar (M) ratio of 1:2
- M molar ratio
- the step (B) is a step of permeating the derivative solution of the antibiotic substance through the enzyme-immobilized porous membrane.
- the derivative solution of the antibiotic substance to be added preferably has a content of 0.8 to 10 parts by weight relative to 100 parts by weight of the porous membrane.
- the permeating step is preferably performed by applying a pressure of 1 to 10 bar in a nitrogen atmosphere through dead-end filtration, cross flow filtration, or a complex manner thereof.
- Tetrakis(4-aminophenyl) methane (TAPM) (MW: 382.50) was dissolved in DMF(N,N-dimethylformide) to prepare an organic solution having a concentration of 4 wt/vol %, and 1,4-hexamethylene diisocyanate (HDI) (MW: 168.19) was dissolved in DMF to prepare an organic solution having a concentration of 4 wt/vol %.
- the tetrakis(4-aminophenyl) methane solution was slowly added to the 1,4-hexamethylene diisocyanate solution, and mixed with each other. The mixed solution was reacted at room temperature in a nitrogen atmosphere for 72 hours, to obtain a mixed solution in a sol-phase.
- Poly ethylene glycol (PEG) having a concentration of 60 wt % was added to the mixed solvent, followed by sufficient stirring.
- the obtained mixture was applied to a glass plate at 50° C. for 1 hour, at 80° C. for 2 hours, and at 100° C. for 3 hours, followed by drying and curing, to finally synthesize a nano composite film of an organic molecular network (TAPM+HDI) and PEG.
- TAPM+HDI organic molecular network
- the synthesized membrane was cooled at room temperature, and precipitated in water to be separated from a substrate.
- the membrane was stirred in water for about one week to remove the water-soluble polymer, polyethylene glycol (PEG), thereby preparing a porous membrane having nano pores.
- PEG polyethylene glycol
- the porous membrane of Preparation Example for immobilizing the enzyme was put into a lower portion 20 of a dead-end cell filtration system as illustrated in FIG. 1 . Then, a penicillin G acylase (PGA) solution having a concentration of 0.4 w/v% was put into an upper portion (inlet, 10) of the dead-end cell filtration system, and stirred. Next, a pressure of 5 bar was applied in a nitrogen atmosphere to prepare a porous membrane in which the penicillin G acylase (PGA) is immobilized.
- PGA penicillin G acylase
- the PGA-immobilized porous membrane prepared by Example 1 above was put into the lower portion 20 of the dead-end cell filtration system. Then, 10 mM p-hydroxyphenylglycine methyl ester (PHPGME) solution and 10 mM 6-aminopenicillanic acid (6-APA) solution were prepared, respectively, by using distilled water as a solvent, and two of the prepared solutions were mixed and put into the upper portion (inlet, 10) of the dead-end cell filtration system. Next, a pressure of 5 bar was applied in a nitrogen atmosphere to permeate the mixed solution of PHPGME and 6-APA through the PGA-immobilized porous membrane, thereby preparing an antibiotic.
- PHPGME p-hydroxyphenylglycine methyl ester
- 6-APA 6-aminopenicillanic acid
- elemental mapping was performed by using an energy-dispersive X-ray spectrometer (JOEL JSM-6700 manufactured by Scanning Electron Microscope), and results thereof were illustrated in FIG. 5A and FIG. 5B .
- JOEL JSM-6700 manufactured by Scanning Electron Microscope
- FIG. 5A is an image illustrating a cross section of the porous membrane according to Example 1.
- the porous membrane is composed of carbon, nitrogen, and oxygen
- the enzyme is composed of carbon, nitrogen, oxygen and sulfur, and thus, whether the enzyme is immobilized could be confirmed by analyzing whether the sulfur element is present.
- the antibiotic substance was separated by using a Phenomenex Gemini C18 column (150 ⁇ 4.6 mm, a particle size of 5 ⁇ m) through a high performance liquid chromatography (HPLC), and was subjected to quantitative analysis by measuring an adsorption amount of the antibiotic with an UV detector at 225 nm
- the conversion amount was calculated by the following Calculation Formula 1, and results thereof were illustrated in FIG. 6 .
- the enzyme capable of promoting the synthesis reaction of the antibiotic substance is able to be stably immobilized in the porous membrane by using the dead-end filtration.
- the antibiotics with a high yield by preparing the antibiotics through the dead-end filtration using the enzyme-immobilized porous membrane.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
The present disclosure relates to an enzyme-immobilized porous membrane and a preparation method of antibiotics using the same, and more specifically, to an enzyme-immobilized porous membrane prepared by immobilizing a specific enzyme through dead-end filtration, and a preparation method of antibiotics with a high yield using the enzyme-immobilized porous membrane.
According to various exemplary embodiments of the present disclosure, the enzyme capable of promoting the synthesis reaction of the antibiotic substance is able to be stably immobilized in the porous membrane by passing the solution of enzyme through the membrane.
In addition, it is possible to provide antibiotics with a high yield by preparing the antibiotics by passing the reactant solution through the enzyme-immobilized porous membrane.
Description
- This application claims the benefit of U.S. Provisional Application No. 62/238,145, filed on Oct. 7, 2015, and Korean Patent Application No. 10-2016-0068897, filed on Jun. 2, 2016 in the KIPO (Korean Intellectual Property Office), both of which are incorporated herein by reference in their entireties.
- 1. Technical Field
- The present disclosure relates to an enzyme-immobilized porous membrane and a preparation method of antibiotics using the same, and more specifically, to an enzyme-immobilized porous membrane prepared by immobilizing a specific enzyme through filtration, and a preparation method of antibiotics with a high yield using the enzyme-immobilized porous membrane.
- 2. Description of the Related Art
- Enzymes are generally useful for various reactions due to high steric and chemical selectivity, and have been used as a catalyst to promote a reaction rate under a mild reaction condition. However, in general, since the enzymes have a high cost, it is economically difficult to be used in an industrially large amount. In addition, most of the enzymes have a limitation in being used for an organic chemical reaction since they are not dissolved in organic solvents. Accordingly, a number of researches to immobilize the enzymes have been conducted to enhance activity and stability of the enzymes and reuse the enzymes.
- There are three methods to immobilize the enzyme in a polymer membrane. The first method is to adsorb the enzyme on a surface of the polymer membrane, the second method is to attach the enzyme to the polymer membrane via a covalent bond by modifying the enzyme, and the third method is an entrapping method in which the enzyme is physically entrapped in pores of the polymer membrane.
- Since the method of adsorbing the enzyme on the surface of the membrane via a non-covalent bond is the easiest and simplest, a number of researches into the adsorption method have been conducted, but the adsorption method is disadvantageous in that the enzyme may be easily leached away, and has relatively low stability.
- In order to solve these disadvantages, there is an attempt to immobilize the enzyme in a porous membrane, and the immobilization method is effective to improve an immobilization rate and an immobilization maintenance rate of the enzyme and is effective in view of economical aspect since the immobilization process is relatively simple.
- Penicillin-based antibiotics are β-lactam-based antibiotics produced by blue mold (Penicillium notatum), etc., and may be synthesized from Penicillium notatum and Penicillium chrysogenum that are called the blue mold.
- In the related art, the antibiotics are synthesized by treating a derivative in a solution state through step-by-step reactions. However, this preparation method causes side reactions such as hydrolysis reaction and thus the final antibiotic substance is produced in a remarkably low yield.
- Therefore, according to the present disclosure, the enzyme-immobilized porous membrane is used to stably immobilize the enzyme capable of promoting reactivity of the antibiotic substance in the porous membrane, thereby improving the reactivity, such that the antibiotic that is a final substance may have an improved yield.
- It is an aspect of the present disclosure to provide a porous membrane in which an enzyme capable of promoting a synthesis reaction of an antibiotic substance is stably immobilized by using dead-end filtration.
- In addition, it is another aspect of the present disclosure to provide a preparation method of antibiotics with a high yield by using the enzyme-immobilized porous membrane.
- The present disclosure is not limited to the above aspect and other aspects of the present disclosure will be clearly understood by those skilled in the art from the following description.
- In accordance with one aspect of the present disclosure, there is provided an enzyme-immobilized porous membrane in which an enzyme promoting a synthesis reaction of an antibiotic substance is immobilized, wherein the porous membrane is three-dimensionally interconnected by pores, the porous membrane forms a three dimensional network by polymerizing a first monomer and a second monomer each having two to four functional groups, the functional group of the first monomer is an amino group, the functional group of the second monomer is an isocyanate group, an acyl halide group or an ester group, the first monomer and/or the second monomer has four functional groups, and the enzyme is at least one selected from the group consisting of penicillin G acylase, penicillin V acylase, and cephalosporin C acylase.
- In accordance with another aspect of the present disclosure, a preparation method of antibiotics includes: (B) permeating a derivative solution of an antibiotic substance through the enzyme-immobilized porous membrane as described above.
- According to various exemplary embodiments of the present disclosure, the enzyme capable of promoting the synthesis reaction of the antibiotic substance is able to be stably immobilized in the porous membrane by using the dead-end filtration.
- Further, it is possible to provide the antibiotics with a high yield by preparing the antibiotics through the dead-end filtration using the enzyme-immobilized porous membrane.
-
FIG. 1 illustrates a dead-end cell filtration system for immobilizing an enzyme according to an exemplary embodiment of the present disclosure. -
FIG. 2 is a diagram illustrating a preparation method in which the enzyme is immobilized in the porous membrane according to the exemplary embodiment of the present disclosure. -
FIG. 3 is a graph illustrating results obtained by adsorbing nitrogen onto or desorbing nitrogen from a PGA-immobilized porous membrane according to Example 1 to measure an adsorption degree or a desorption degree. -
FIG. 4 is a graph illustrating results obtained by measuring a size of pores formed on the PGA-immobilized porous membrane according to Example 1. -
FIG. 5A is an image illustrating a cross section of the PGA-immobilized porous membrane according to Example 1, andFIG. 5B is an image illustrating results obtained by elemental mapping on the PGA-immobilized porous membrane according to Example 1 using an energy-dispersive X-ray spectrometer. -
FIG. 6 is a graph illustrating results obtained by measuring a yield of the antibiotic prepared by Example 2. - Hereinafter, various aspects and exemplary embodiments of the present disclosure will be described in detail.
- According to one aspect of the present disclosure, there is provided an enzyme-immobilized porous membrane in which an enzyme promoting a synthesis reaction of an antibiotic substance is immobilized, wherein the porous membrane is three-dimensionally interconnected by pores, the porous membrane forms a three-dimensional network by polymerizing a first monomer and a second monomer each having two to four functional groups, the functional group of the first monomer is an amino group, the functional group of the second monomer is an isocyanate group, an acyl halide group or an ester group, at least one of the first monomer or the second monomer has four functional groups, and the enzyme is at least one selected from the group consisting of penicillin G acylase, penicillin V acylase, and cephalosporin C acylase.
- The enzymes are characterized by promoting a synthesis reaction of an antibiotic substance, and among them, the penicillin G acylase is an enzyme capable of promoting reactions of Reaction Schemes 1 and 2 below:
- Firstly, as shown in Reaction Scheme 1 above, carboxylic acid and 6-aminopenicillanic acid (6-APA) may be produced by promoting a hydrolysis reaction of an amide group.
- Secondly, as shown in Reaction Scheme 2 below, a reaction of synthesizing penicillin-based amoxicillin which is a beta-lactam-based antibiotic may be promoted, and specifically, the penicillin may be synthesized by promoting a reaction of an ester group of p-hydroxyphenylglycine methyl ester (PHPGME) and an amine group of 6-APA to form an amide group:
- The penicillin G acylase enzyme may act as a catalyst effective for promoting reactivity in synthesizing the penicillin-based antibiotic, but has a problem in that stability thereof is degraded due to the hydrolysis as shown in Reaction Scheme 1 above.
- Accordingly, in the present disclosure, the enzyme is immobilized in the porous membrane to prevent decomposition or leaching of the enzyme, such that stability of the enzyme may be secured.
- In addition, antibiotics with a high yield may be prepared only by a relatively simple process in which a derivative of the antibiotic substance is permeated through the porous membrane in which the enzyme having secured stability is immobilized. Specifically, the enzyme-immobilized porous membrane described above in the present disclosure includes the porous membrane forming a three-dimensional network and an enzyme that is trapped in the pores of the porous membrane. The porous membrane may include the pores having a size of 5 to 100 nm while forming a three-dimensionally cross-linked monolith, and the pores may be connected to each other, such that the enzyme immobilized in the porous membrane is able to be in contact with reaction substrates in all directions, and a solution may be easily spread, which prevent a problem that substance transport is degraded due to the enzyme blocking the pores.
- In addition, in order for the enzyme to be immobilized in the porous membrane, it is generally known that the size of the pore is 20 to 50 nm (Membrane-Based Synthesis of Nanomaterials, Charles R. Martin), and the porous membrane of the present disclosure is characterized by immobilizing various sizes of enzymes since it has various ranges of nano pores having a size of 5 to 100 nm as well as pores having a size in micro range.
- The porous membrane of the present disclosure may be obtained by mixing an organic sol with a polymer solution to obtain a micro porous membrane, the organic sol consisting of an organic network structure in which the first monomer having an amino group is polymerized with the second monomer having an isocyanate group, an acyl halide group or an ester group that is the functional group polymerizable with the amino group, and removing the polymer from the micro porous membrane by using water.
- According to an exemplary embodiment of the present disclosure, the first monomer may have two to four amino groups, and the second monomer may have two to four functional groups selected from the group consisting of the isocyanate group, the acyl halide group, and the ester group. The first monomer having two to four amino groups may be C1-C100 aliphatic compound substituted with two to four amino groups or C6-C100 aromatic compound substituted with two to four amino groups.
- The second monomer having two to four isocyanate groups, the two to four acyl halide groups, or the two to four ester groups may be C1-C100 aliphatic compound substituted with two to four isocyanate groups, the two to four acyl halide groups, or the two to four ester groups or C6-C100 aromatic compound substituted with two to four isocyanate groups, the two to four acyl halide groups, or the two to four ester groups.
- As an example, the first monomer and the second monomer may be compounds represented by Chemical Formulas 1 to 9 below:
- in Chemical Formulas 1 to 9 above, R is an amino group, an isocyanate group, an acyl halide group or an ester group.
- In addition, according to an exemplary embodiment of the present disclosure, the first monomer and the second monomer may be a compound represented by Chemical
-
Formula 10 below: - in Chemical Formula 10 above, R is an amino group, an isocyanate group, an acyl halide group or an ester group, and n is 0 or 1.
- The first monomer and the second monomer may be polymerized by a nucleophilic addition or substitution reaction between the amino group of the first monomer and the isocyanate group, the acyl halide group or the ester group of the second monomer, and polymers to be produced may cause additional nucleophilic addition or substitution reaction by non reacted negative (−), positive (+) functional groups to generate a crosslinking reaction between the polymers. As a result, the monomer having the four functional groups may form a kind of crosslinking point as a tetrahedral structure, and may form the three-dimensional organic network structure linked by a strong covalent bond on the basis of the crosslinking point.
- Specifically, the organic network structure formed by the polymerization reaction between the first monomer and the second monomer may be three-dimensionally polymerized and cross-linked to have a number of fine pores and a large specific surface area, and to have excellent chemical resistance, heat resistance, and durability by a high crosslinking rate and the strong covalent bond.
- In addition, the monomer having two to four amino groups may be, for example, tetrakis(4-aminophenyl)methane (TAPM), p-phenylene diamine (PDA), or 4,4′-oxydianiline (ODA), but these examples thereof are not limited thereto.
- Further, the monomer having two to four isocyanate groups may be, for example, p-phenylene diisocyanate (PDI), hexamethylene diisocyanate (HDI), or tetrakis(4-isocyanatophenyl) methane (TIPM), but these examples thereof are not limited thereto.
- According to an exemplary embodiment of the present disclosure, the porous membrane may be formed by polymerizing a monomer represented by Chemical Formula 11 below and the monomer having two isocyanate groups:
- in Chemical Formula 11 above, X is a carbon atom or a silicon atom.
- Further, according to another exemplary embodiment of the present disclosure, the porous membrane may be formed by polymerizing the monomer having two amino groups and a monomer represented by Chemical Formula 12 below:
- in Chemical Formula 12 above, X is a carbon atom or a silicon atom.
- The porous membrane may have a flat sheet structure or a hollow fiber membrane structure.
- In addition, the porous membrane may have a single layered structure or a plurality of layered structure.
- According to another aspect of the present disclosure, there is provided a preparation method of antibiotics including: (B) permeating a derivative solution of an antibiotic substance through the enzyme-immobilized porous membrane.
- The preparation method preferably further includes step (A) of preparing the derivative solution of the antibiotic substance.
- According to the related art, the derivative of the antibiotic substance is prepared in a solution state, and is treated with step-by-step reactions, thereby preparing the antibiotics. The preparation method of the antibiotics through the step-by-step reactions has problems in that the finally produced antibiotic substance has a remarkably low yield, and a large amount of impurities are caused due to the hydrolysis reaction or the addition reaction of the enzyme.
- Accordingly, according to the present disclosure, stability of the enzyme is firstly secured by immobilizing the enzyme in the porous membrane, and then, the antibiotics with a high yield are prepared only by a simple process of permeating the derivative of the antibiotic substance through the enzyme-immobilized porous membrane.
- Specifically, step (A) is a step of preparing the derivative solution of the antibiotic substance capable of preparing the antibiotic substance.
- The derivative of the antibiotic substance preferably includes the first derivative and the second derivative, and the first derivative and the second derivative may be different from each other, and the first derivative or the second derivative may be at least one selected from the group consisting of 6-aminopenicillanic acid (6-APA), p-hydroxyphenylglycine methyl ester (PHPGME), 7-aminodesacetoxycephalosporanic acid, and phenylglycine.
- The step (A) may include (a-1) preparing a first derivative solution; (a-2) preparing a second derivative solution; and (a-3) mixing the first derivative solution with the second derivative solution.
- The step (a-1) is a step of preparing the first derivative solution, wherein the first derivative solution preferably has a concentration of 1 to 20 mM by adding a solvent to the first derivative. When the concentration of the first derivative solution is less than 1 mM, it is not preferred since the concentration is too thin, reactivity with the enzyme may be degraded, and when the concentration thereof is more than 20 mM, an amount of the reaction substance is increased as compared to an amount of the enzyme.
- The step (a-2) is a step of preparing the second derivative solution, wherein the second derivative solution preferably has a concentration of 1 to 20 mM by adding a solvent to the second derivative, which is similar to the step (a-1).
- The solvent is preferably distilled water, but the present disclosure is not limited thereto.
- The step (a-3) is a step of mixing the first derivative solution with the second derivative solution, wherein the first derivative and the second derivative are preferably mixed at a molar (M) ratio of 1:1 to 3. When the molar ratio is out of the above-described range, it is not preferred since reactivity may be degraded.
- In particular, it is confirmed that when the first derivative is 6-aminopenicillanic acid, the second derivative is p-hydroxyphenylglycine methyl ester, and the 6-amino-penicillanic acid is mixed with the p-hydroxyphenylglycine methyl ester at a molar (M) ratio of 1:2, a penicillin-based antibiotic to be synthesized has the most effective yield as about 70%, and when the molar ratio is out of the above-described range, the yield is rapidly reduced.
- The step (B) is a step of permeating the derivative solution of the antibiotic substance through the enzyme-immobilized porous membrane.
- Here, the derivative solution of the antibiotic substance to be added preferably has a content of 0.8 to 10 parts by weight relative to 100 parts by weight of the porous membrane.
- The permeating step is preferably performed by applying a pressure of 1 to 10 bar in a nitrogen atmosphere through dead-end filtration, cross flow filtration, or a complex manner thereof.
- In particular, it is confirmed that when 1 to 5 parts by weight of the derivative solution of the antibiotic substance is permeated through the dead-end filtration at a pressure of 5 bar in a nitrogen atmosphere, the amount of impurities contained in the antibiotic which is the final product is rapidly reduced.
- Hereinafter, the present disclosure will be described in detail with reference to the following Examples, etc. Therefore, it should be understood that the foregoing embodiments are provided for illustrative purposes only and are not to be construed in any way as limiting the present disclosure. In addition, as long as a person skilled in the art practices the present disclosure based on the disclosed description of the present disclosure including the following examples, it is obvious that the present disclosure may be easily practiced by the person skilled in the art even though testing results are not specifically provided, and it is natural that various modifications and changes are included in the accompanying claims.
- In addition, experimental results below are only representative experimental results of Examples and Comparative Examples of the present disclosure, and respective effects of various embodiments of the present disclosure that are not presented explicitly below are described in detail in corresponding sections.
- (1) Preparation of (TAPM+HDI/PEG) nano composite film
- Tetrakis(4-aminophenyl) methane (TAPM) (MW: 382.50) was dissolved in DMF(N,N-dimethylformide) to prepare an organic solution having a concentration of 4 wt/vol %, and 1,4-hexamethylene diisocyanate (HDI) (MW: 168.19) was dissolved in DMF to prepare an organic solution having a concentration of 4 wt/vol %. Next, the tetrakis(4-aminophenyl) methane solution was slowly added to the 1,4-hexamethylene diisocyanate solution, and mixed with each other. The mixed solution was reacted at room temperature in a nitrogen atmosphere for 72 hours, to obtain a mixed solution in a sol-phase.
- Poly ethylene glycol (PEG) having a concentration of 60 wt % was added to the mixed solvent, followed by sufficient stirring. The obtained mixture was applied to a glass plate at 50° C. for 1 hour, at 80° C. for 2 hours, and at 100° C. for 3 hours, followed by drying and curing, to finally synthesize a nano composite film of an organic molecular network (TAPM+HDI) and PEG.
- (2) Preparation of TAPM+HDI Porous Membrane—Removal of PEG
- The synthesized membrane was cooled at room temperature, and precipitated in water to be separated from a substrate. The membrane was stirred in water for about one week to remove the water-soluble polymer, polyethylene glycol (PEG), thereby preparing a porous membrane having nano pores.
- The porous membrane of Preparation Example for immobilizing the enzyme was put into a
lower portion 20 of a dead-end cell filtration system as illustrated inFIG. 1 . Then, a penicillin G acylase (PGA) solution having a concentration of 0.4 w/v% was put into an upper portion (inlet, 10) of the dead-end cell filtration system, and stirred. Next, a pressure of 5 bar was applied in a nitrogen atmosphere to prepare a porous membrane in which the penicillin G acylase (PGA) is immobilized. - First, the PGA-immobilized porous membrane prepared by Example 1 above was put into the
lower portion 20 of the dead-end cell filtration system. Then, 10 mM p-hydroxyphenylglycine methyl ester (PHPGME) solution and 10 mM 6-aminopenicillanic acid (6-APA) solution were prepared, respectively, by using distilled water as a solvent, and two of the prepared solutions were mixed and put into the upper portion (inlet, 10) of the dead-end cell filtration system. Next, a pressure of 5 bar was applied in a nitrogen atmosphere to permeate the mixed solution of PHPGME and 6-APA through the PGA-immobilized porous membrane, thereby preparing an antibiotic. - (Provided that, the dead-end cell filtration system was used as the same as that of Example 1 above.)
- In order to confirm a pore size of the PGA-immobilized porous membrane according to Example 1, nitrogen was added and adsorbed onto or desorbed from the porous membrane. Results thereof were illustrated in
FIG. 3 . - Referring to
FIG. 3 , it could be appreciated that an adsorption and desorption curve ofType 4 isotherm was obtained, and the pores were well-formed in the porous membrane. The size of the thus formed pores was measured, and illustrated inFIG. 4 . Referring toFIG. 4 , it could be confirmed that the pore size of the porous membrane had an average diameter of 5 to 30 nm - In order to confirm whether the enzyme was well immobilized in the PGA-immobilized porous membrane of Example 1, elemental mapping was performed by using an energy-dispersive X-ray spectrometer (JOEL JSM-6700 manufactured by Scanning Electron Microscope), and results thereof were illustrated in
FIG. 5A andFIG. 5B . -
FIG. 5A is an image illustrating a cross section of the porous membrane according to Example 1. - The porous membrane is composed of carbon, nitrogen, and oxygen, and the enzyme is composed of carbon, nitrogen, oxygen and sulfur, and thus, whether the enzyme is immobilized could be confirmed by analyzing whether the sulfur element is present.
- Accordingly, as a result obtained by performing the elemental mapping with regard to the sulfur element, it could be appreciated that the sulfur elements represented by white dots were uniformly distributed as illustrated in
FIG. 5B . Specifically, it could be confirmed that the enzyme was uniformly distributed in the inside of the cross section of the porous membrane. - In order to quantitatively analyze the antibiotic prepared by Example 2, the antibiotic substance was separated by using a Phenomenex Gemini C18 column (150×4.6 mm, a particle size of 5 μm) through a high performance liquid chromatography (HPLC), and was subjected to quantitative analysis by measuring an adsorption amount of the antibiotic with an UV detector at 225 nm The conversion amount was calculated by the following Calculation Formula 1, and results thereof were illustrated in
FIG. 6 . -
Conversion (%)=(experimental amoxicillin amount/theoretical amoxicillin amount)×100 [Calculation Formula 11] - Referring to
FIG. 6 , it could be confirmed that about 70% constant conversion was obtained. The result value was significantly improved as compared to a yield obtained by the existing preparation method of antibiotics, and reactivity was improved due to the reaction in which the enzyme immobilized in the porous membrane was promoted, which indicated that the antibiotics with a high yield could be prepared. - Therefore, according to various exemplary embodiments of the present disclosure, the enzyme capable of promoting the synthesis reaction of the antibiotic substance is able to be stably immobilized in the porous membrane by using the dead-end filtration.
- Further, it is possible to provide the antibiotics with a high yield by preparing the antibiotics through the dead-end filtration using the enzyme-immobilized porous membrane.
- Although some embodiments have been disclosed herein, it should be understood by those skilled in the art that these embodiments are provided by way of illustration only, and that various modifications, changes, and alterations can be made without departing from the spirit and scope of the invention. Therefore, it should be understood that the foregoing embodiments are provided for illustrative purposes only and are not to be construed in any way as limiting the present disclosure.
Claims (10)
1. An enzyme-immobilized porous membrane in which an enzyme promoting a synthesis reaction of an antibiotic substance is immobilized,
wherein the porous membrane is three-dimensionally interconnected by pores,
the porous membrane forms a three-dimensional network by polymerizing a first monomer and a second monomer each having two to four functional groups,
the functional group of the first monomer is an amino group,
the functional group of the second monomer is an isocyanate group, an acyl halide group or an ester group,
the first monomer and/or the second monomer has four functional groups, and
the enzyme is at least one selected from the group consisting of penicillin G acylase, penicillin V acylase, and cephalosporin C acylase.
2. The enzyme-immobilized porous membrane according to claim 1 , wherein the antibiotic substance is a penicillin-based substance, or a cephalosporin-based substance.
3. A preparation method of antibiotics comprising:
(B) permeating a derivative solution of an antibiotic substance through the enzyme-immobilized porous membrane according to claim 1 .
4. The preparation method according to claim 3 , wherein the derivative of the antibiotic substance includes a first derivative and a second derivative,
the first derivative and the second derivative are mixed at a molar (M) ratio of 1:1 to 3,
the first derivative and the second derivative are different from each other, and are each independently at least one selected from the group consisting of 6-aminopenicillanic acid, p-hydroxyphenylglycine methyl ester, 7-aminodesacetoxycephalosporanic acid, and phenylglycine.
5. The preparation method according to claim 4 , wherein the first derivative is the 6-aminopenicillanic acid, and the second derivative is the p-hydroxyphenylglycine methyl ester.
6. The preparation method according to claim 3 , further comprising:
(A) preparing the derivative solution of the antibiotic substance, wherein step (A) includes:
(a-1) preparing a first derivative solution;
(a-2) preparing a second derivative solution; and
(a-3) mixing the first derivative solution with the second derivative solution.
7. The preparation method according to claim 3 , wherein the permeating of step (B) is performed by dead-end filtration.
8. The preparation method according to claim 3 , wherein step (B) is performed at a pressure of 2 to 7 bar in a nitrogen atmosphere.
9. The preparation method according to claim 3 , wherein the antibiotic substance is a penicillin-based substance, or a cephalosporin-based substance.
10. A preparation method of antibiotics comprising:
(B) permeating a derivative solution of an antibiotic substance through the enzyme-immobilized porous membrane according to claim 2 .
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/288,190 US20170101660A1 (en) | 2015-10-07 | 2016-10-07 | Enzyme-immobilized porous membrane and preparation method of antibiotics using the same |
| US16/658,705 US11359224B2 (en) | 2015-10-07 | 2019-10-21 | Enzyme-immobilized porous membrane and preparation method of antibiotics using the same |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238145P | 2015-10-07 | 2015-10-07 | |
| KR1020160068897A KR101850958B1 (en) | 2015-10-07 | 2016-06-02 | Porous network membrane immobilized enzyme and preparation method of antibiotics using the same |
| KR10-2016-0068897 | 2016-06-02 | ||
| US15/288,190 US20170101660A1 (en) | 2015-10-07 | 2016-10-07 | Enzyme-immobilized porous membrane and preparation method of antibiotics using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16/658,705 Division US11359224B2 (en) | 2015-10-07 | 2019-10-21 | Enzyme-immobilized porous membrane and preparation method of antibiotics using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20170101660A1 true US20170101660A1 (en) | 2017-04-13 |
Family
ID=58498814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/288,190 Abandoned US20170101660A1 (en) | 2015-10-07 | 2016-10-07 | Enzyme-immobilized porous membrane and preparation method of antibiotics using the same |
| US16/658,705 Active 2037-09-12 US11359224B2 (en) | 2015-10-07 | 2019-10-21 | Enzyme-immobilized porous membrane and preparation method of antibiotics using the same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16/658,705 Active 2037-09-12 US11359224B2 (en) | 2015-10-07 | 2019-10-21 | Enzyme-immobilized porous membrane and preparation method of antibiotics using the same |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US20170101660A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112986289A (en) * | 2021-02-02 | 2021-06-18 | 海南海力制药有限公司 | Consistency evaluation and detection method of amoxicillin capsules |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5801011A (en) * | 1992-04-24 | 1998-09-01 | Eli Lilly And Company | Process for preparing cephalosporins with penicillin acylase without pH control |
| US20150099288A1 (en) * | 2013-04-10 | 2015-04-09 | Gwangju Institute Of Science And Technology | Porous membrane having immobilized enzyme, porous membrane composite including the same, and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1274658B (en) * | 1995-02-28 | 1997-07-18 | Acs Dobfar Spa | IMPROVED ENZYMATIC PROCEDURE FOR THE PRODUCTION OF PENICILLINS AND CEPHALOSPORINS |
| NL1007302C2 (en) | 1997-10-17 | 1999-04-20 | Dsm Nv | Method for the preparation of a ß-lactam antibiotic. |
-
2016
- 2016-10-07 US US15/288,190 patent/US20170101660A1/en not_active Abandoned
-
2019
- 2019-10-21 US US16/658,705 patent/US11359224B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5801011A (en) * | 1992-04-24 | 1998-09-01 | Eli Lilly And Company | Process for preparing cephalosporins with penicillin acylase without pH control |
| US20150099288A1 (en) * | 2013-04-10 | 2015-04-09 | Gwangju Institute Of Science And Technology | Porous membrane having immobilized enzyme, porous membrane composite including the same, and preparation method thereof |
| US9840701B2 (en) * | 2013-04-10 | 2017-12-12 | Gwangju Institute Of Science And Technology | Porous membrane having immobilized enzyme, porous membrane composite including the same, and preparation method thereof |
| US10202596B2 (en) * | 2013-04-10 | 2019-02-12 | Gwangju Institute Of Science And Technology | Porous membrane having immobilized enzyme, porous membrane composite including the same, and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| US APPLICATION 14/508 414 (Year: 2019) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112986289A (en) * | 2021-02-02 | 2021-06-18 | 海南海力制药有限公司 | Consistency evaluation and detection method of amoxicillin capsules |
Also Published As
| Publication number | Publication date |
|---|---|
| US11359224B2 (en) | 2022-06-14 |
| US20200063175A1 (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lu et al. | Homochiral MOF–polymer mixed matrix membranes for efficient separation of chiral molecules | |
| US10780401B2 (en) | Highly selective alicyclic polyamide nanofiltration membrane and making method thereof | |
| CN106102884B (en) | Composite membrane comprising graphene oxide coating layer, porous polymer support comprising the same, and preparation method thereof | |
| KR101565031B1 (en) | Porous monolithic organic network membrane immobilized enzyme and preparation method thereof | |
| BR112013023998B1 (en) | FUNCTIONAL SUBSTRATES WITH BINDERS AND METHOD FOR SEPARATING A BIOLOGICAL SPECIES FROM A FLUID | |
| US20120114947A1 (en) | Polymer-functionalized carbon nanotube, process for its production and use | |
| US20130228520A1 (en) | Polymer coatings that resist adsorption of proteins | |
| CN111298660B (en) | Preparation method of anti-fouling composite nanofiltration membrane with strong stability | |
| US11359224B2 (en) | Enzyme-immobilized porous membrane and preparation method of antibiotics using the same | |
| Xu et al. | Fabrication of a robust MOF/aerogel composite via a covalent post-assembly method | |
| Samuneva et al. | Sol–gel synthesis and structure of silica hybrid biomaterials | |
| KR20190112693A (en) | Membranes and method for producing membranes | |
| CN108410003A (en) | A kind of preparation of modified polyacrylonitrile film and its method applied to immobilized enzyme | |
| KR20110010931A (en) | Polyurea porous body and its manufacturing method | |
| JPS5850522B2 (en) | Composite semipermeable membrane and its manufacturing method | |
| JP2020537535A5 (en) | ||
| KR101850958B1 (en) | Porous network membrane immobilized enzyme and preparation method of antibiotics using the same | |
| Zhang et al. | pH and temperature responsive porous membranes via an in situ bulk copolymerization approach | |
| EP2992947A1 (en) | Method for the preparation of microporous organic membranes, microporous organic membranes and use of same | |
| CN1481409A (en) | Modified sulfonamide polymers | |
| KR20070017740A (en) | Method for producing aromatic polyamide composite membrane | |
| CN119113829A (en) | Lithium ion selective permeable membrane and preparation method and application thereof | |
| KR102210912B1 (en) | Sparator membrane comprising graphene oxide coating layer having improved stability and preparation method thereof | |
| JPH05329346A (en) | Composite semipermeable membrane | |
| KR101496375B1 (en) | Composition of resin for alkylcellulose-polyarcrylonitrile membrane having excellent fouling resistance, Alkylcellulose-polyarcrylonitrile membrane and Manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY, KOREA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARK, JI-WOONG;SHIN, SUNOH;REEL/FRAME:039966/0071 Effective date: 20160926 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |